March 20, 2014
1 min read

Aerie reports net loss for fourth quarter, full year

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Aerie Pharmaceuticals reported a GAAP net loss of $10.3 million, or $0.62 per share, for the fourth quarter ending Dec. 31, 2013, bringing the year-end GAAP net loss to $31.6 million, or $6.38 per share, according to a press release.

GAAP net loss was $3.8 million, or $4.01 per share, and $15.6 million, or $16.39 per share, for the respective time periods the prior year.

Aerie reported being on track with clinical programs for triple-action ophthalmic solution candidate AR-13324 and quadruple-action ophthalmic solution candidate PG324. Proposed trade names for the solutions are Rhopressa and Roclatan, respectively.

Phase 3 trials of Rhopressa are expected to begin early in the third quarter, with efficacy data projected to be available in the middle of 2015. A phase 2b study of Roclatan is under way, with efficacy data projected to be available later this year.